The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on prostate cancer active surveillance.

The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...

MRI should be considered an adjunct to, and not a replacement for, biopsies for men on active surveillance for prostate cancer. MRI does not consistently rule out the presence of Gleason grade ...

The Fusion Biopsy Market is witnessing rapid growth, driven by increasing adoption of precision diagnostic techniques for prostate cancer and other malignancies. Fusion biopsy, which combines MRI and ...

Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided ...

Mark Hinton, CTO at Lucida Medical, said: “Pi is medical device software that is CE-approved for use in clinics. We developed ...

A new study published in the journal of Research and Reports in Urology showed that lesion size was a crucial predictor of ...

The 18-gene MyProstateScore 2.0 biomarker test was designed to reduce overdiagnosis of low-grade prostate cancers.

A new at-home urine test for prostate cancer developed by Michigan researchers aims to encourage more men to undergo diagnostic testing.